PT-141 for women explained: how bremelanotide works, FDA-approved dosing, side effects, and what research says about this peptide for desire.
PT-141 (bremelanotide) is a prescription peptide that the FDA approved in 2019 for premenopausal women with hypoactive sexual desire disorder, or HSDD. It is sold under the brand name Vyleesi and injected under the skin at least 45 minutes before sexual activity. It works on receptors in the brain rather than on blood flow, which separates it from most other sexual-health drugs.
What PT-141 Is and How It Works
Bremelanotide is a synthetic version of alpha-melanocyte-stimulating hormone, a peptide the body produces naturally. It activates melanocortin receptors, primarily MC4R, in the central nervous system.
That brain-first mechanism matters. PDE5 inhibitors like sildenafil and tadalafil relax blood vessels and improve blood flow, but low desire in women is usually not a blood-flow problem. PT-141 targets neurological pathways tied to desire and arousal instead.
PT-141 is not a hormone. It does not raise estrogen, progesterone, or testosterone, and it is not a testosterone replacement product.
Is PT-141 FDA-Approved for Women?
Yes, but only for a specific group. Vyleesi is approved for premenopausal women with acquired, generalized HSDD — low desire that developed over time rather than existing for a lifetime, and that shows up in most situations rather than only with one partner.
PT-141 is not approved for men, and it is not approved for postmenopausal women because that group was not included in the registration trials. Use outside those parameters is off-label.
Compounded or research-grade vials sold online are a different product entirely. They are not FDA-approved, their strength and purity are not verified, and they should never be treated as interchangeable with the pharmacy version.
Does PT-141 Work for Women?
Clinical trials show a real but modest effect. In the two pivotal RECONNECT studies, premenopausal women with HSDD who used bremelanotide reported roughly one more satisfying sexual event per month than women who received a placebo.
That average hides wide variation. Some women notice clear improvement in desire and less distress about low libido; others feel nothing except side effects. Because the average benefit is small, many clinicians frame PT-141 as one option worth trying rather than a guaranteed fix.
The pt-141 for women benefits documented in research center on desire and personal distress, not on lubrication, orgasm intensity, or hormone levels. PT-141 is not a cure for low desire, and it does not address relationship or psychological causes.
PT-141 Dosage for Women
The approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh, at least 45 minutes before anticipated sexual activity. Dosing is limited to one injection in any 24-hour period and no more than eight injections per month.
Standard medical guidance on pt-141 dosage for women does not include daily use. If a dose does not produce a response, taking more is not recommended, because higher doses in early trials were linked to more nausea and vomiting without a clear gain in benefit.
A pt-141 dosage calculator for women found on a website should never replace a prescriber's instructions, since the approved dose is fixed and does not scale with body weight.
| Dose | Status | Key notes |
|---|---|---|
| 1.75 mg subcutaneous | FDA-approved for premenopausal HSDD | One dose per 24 hours; maximum 8 doses per month |
| 1.25 mg subcutaneous | Studied in trials, not the approved dose | Lower strength tested in phase 2 research |
| 10 mg | Not approved for women | Higher strengths were studied mainly with other routes and populations; nausea and vomiting rose with dose |
PT-141 Side Effects and Safety
Nausea is the most commonly reported side effect and affected roughly 40 percent of participants in the clinical trials. Flushing, headache, and injection site reactions are also frequent.
- Nausea and vomiting — typically within the first hour after injection
- Flushing and warmth — temporary, related to widened blood vessels
- Headache — reported by a substantial share of users
- Injection site reactions — pain, bruising, or irritation where the needle goes in
- Focal hyperpigmentation — dark patches on the skin, gums, or breasts with repeated use, which may not fade completely
Blood pressure rises briefly after an injection. The product carries a warning and is contraindicated in women with uncontrolled high blood pressure or known cardiovascular disease.
Anyone researching pt-141 for women side effects should also know that combining it with blood pressure medication, antidepressants, or alcohol has not been well studied. Tell your prescriber about every medication and supplement you take.
How PT-141 Compares With Other Options
PT-141 is one of only a few medications approved for low sexual desire in women in the United States. The table below shows where it sits among the most discussed options.
| Option | How it is used | FDA status for women | Typical effect |
|---|---|---|---|
| Bremelanotide (PT-141 / Vyleesi) | Subcutaneous injection 45 minutes before activity | Approved for premenopausal acquired, generalized HSDD | About one extra satisfying sexual event per month on average |
| Flibanserin (Addyi) | Oral tablet taken at bedtime | Approved for premenopausal HSDD | Modest increase in satisfying sexual events |
| Testosterone therapy | Off-label, several forms | Not approved for women in the US | Mixed evidence; long-term safety data are limited |
| Sildenafil or tadalafil | Oral | Not approved for women | Inconsistent results in female trials |
Who Should Talk to a Doctor First
PT-141 is a prescription medication and it is not appropriate for everyone. Women with uncontrolled hypertension, cardiovascular disease, or a history of focal hyperpigmentation should weigh the risks with a clinician before starting.
Low desire can also have causes that a peptide will not fix, including relationship stress, medication side effects, thyroid problems, depression, and menopause. A healthcare professional can identify which factors are at play before adding a drug to the picture.
The Bottom Line
PT-141 is an FDA-approved option for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and it works differently from anything else on the market. Its average benefit in trials is modest, its most common side effect is nausea, and it requires a prescription.
Compounded peptides sold online are not the same as the approved product, and self-dosing based on internet calculators is risky. Ask a healthcare professional whether PT-141 fits your situation and your health history.
Frequently Asked Questions
Does PT-141 work for women?
Yes, but the effect is modest. In the pivotal RECONNECT trials, premenopausal women with hypoactive sexual desire disorder who used bremelanotide reported about one more satisfying sexual event per month than those on placebo. Some women see clear improvement in desire, while others notice little benefit beyond side effects.
What is the FDA-approved PT-141 dosage for women?
The approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh at least 45 minutes before sexual activity. No more than one dose should be used in 24 hours, and no more than eight doses per month. Higher doses have not been approved and are linked to more nausea.
What are the most common PT-141 side effects in women?
Nausea is the most common side effect, reported by roughly 40 percent of participants in clinical trials. Flushing, headache, vomiting, and injection site reactions are also frequent. PT-141 can raise blood pressure briefly and is contraindicated in women with uncontrolled hypertension or cardiovascular disease.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.